Guenter R. Janhofer is the Chief Medical Officer since February 2018. He has spent more than 30 years in the healthcare industry in roles of increasing complexity and scope. Before joining Erydel, Guenter served as the Head of Development and then Chief Medical Officer at BTG, a British healthcare company specialized in interventional medicine across a broad spectrum of disease areas, ranging from interventional oncology to pulmonology to vascular diseases, and comprising drugs, biologicals and drug device combinations. Guenter was responsible for the successful completion of the clinical development program of several compounds and subsequent regulatory approval by the FDA. Prior to his tenure at BTG, Guenter had a career at Merck, Inc., both in European subsidiaries as the respective Medical Director as well as at Merck’s US headquarters as Vice President for Global Medical and Scientific Affairs. He received his MD from the University of Hamburg, Germany, and holds PhDs in Climatology and Medicine as well as a post doc degree (Habilitation) from the University of Technology in Berlin.